Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...

Clinical Trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Phase 1

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: BIIB054

First Posted Date: 2018-10-23

Last Posted Date: 2021-05-25

Lead Sponsor: Biogen

Target Recruit Count: 24

Registration Number: NCT03716570

Locations: 🇯🇵
Research Site, Kodaira-shi, Tokyo-To, Japan

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

Phase 2

Completed

Conditions: Bipolar Disorder I
Bipolar Disorder II
Major Depressive Episode

Interventions: Drug: SAGE-217
Drug: Placebo

First Posted Date: 2018-10-02

Last Posted Date: 2023-12-13

Lead Sponsor: Biogen

Target Recruit Count: 35

Registration Number: NCT03692910

Locations: 🇺🇸
Sage Investigational Site, Richardson, Texas, United States

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Phase 3

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Natalizumab

First Posted Date: 2018-10-01

Last Posted Date: 2024-06-12

Lead Sponsor: Biogen

Target Recruit Count: 585

Registration Number: NCT03689972

Locations: 🇧🇪
CHU de Tivoli, La Louvière, Belgium
🇺🇸
MS Center of California, Laguna Hills, California, United States
🇺🇸
UCI MIND, Irvine, California, United States

and more 104 locations

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: SAGE-217
Drug: Placebo

First Posted Date: 2018-09-14

Last Posted Date: 2023-11-29

Lead Sponsor: Biogen

Target Recruit Count: 581

Registration Number: NCT03672175

Locations: 🇺🇸
Site Investigational Site, Decatur, Georgia, United States
🇺🇸
Sage Investigational Site, Charlottesville, Virginia, United States

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Completed

Conditions: Arthritis, Psoriatic
Arthritis, Rheumatoid
Spondylitis, Ankylosing
Crohn's Disease
Colitis, Ulcerative

Interventions: Drug: Adalimumab
Drug: Infliximab

First Posted Date: 2018-09-10

Last Posted Date: 2022-10-18

Lead Sponsor: Biogen

Target Recruit Count: 2274

Registration Number: NCT03662919

Locations: 🇫🇷
Research Site, Toulon, Provence-Alpes-Côte d'Azur, France
🇫🇷
Research Site 2, La Rochelle, Nouvelle-Aquitaine, France
🇫🇷
Research Site 3, Paris, Ile De France, France

and more 8 locations

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

Phase 2

Terminated

Conditions: Alzheimer's Disease
Cognitive Dysfunction

Interventions: Drug: Aducanumab
Drug: Placebo

First Posted Date: 2018-08-21

Last Posted Date: 2021-09-16

Lead Sponsor: Biogen

Target Recruit Count: 52

Registration Number: NCT03639987

Locations: 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸
Pacific Research Network, Inc, San Diego, California, United States
🇺🇸
Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States

and more 18 locations

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

Phase 3

Withdrawn

Conditions: Trigeminal Neuralgia

Interventions: Drug: BIIB074
Drug: Placebo

First Posted Date: 2018-08-20

Last Posted Date: 2023-05-06

Lead Sponsor: Biogen

Registration Number: NCT03637387

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: BIIB078
Drug: Placebo

First Posted Date: 2018-08-10

Last Posted Date: 2022-01-14

Lead Sponsor: Biogen

Target Recruit Count: 106

Registration Number: NCT03626012

Locations: 🇬🇧
Research Site, London, United Kingdom

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BG00011
Drug: Placebo

First Posted Date: 2018-06-29

Last Posted Date: 2020-12-11

Lead Sponsor: Biogen

Target Recruit Count: 109

Registration Number: NCT03573505

Locations: 🇬🇧
Research Site, Leeds, West Yorkshire, United Kingdom
🇺🇸
Reserach Site, Houston, Texas, United States

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

Phase 2

Completed

Conditions: Choroideremia

Interventions: Drug: BIIB111

First Posted Date: 2018-04-25

Last Posted Date: 2024-02-23

Lead Sponsor: Biogen

Target Recruit Count: 66

Registration Number: NCT03507686

Locations: 🇩🇪
Research Site, Tübingen, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy